BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

AstraZeneca PLC (AZN) to Cut 625 Jobs


12/5/2012 7:16:02 AM

The bleeding continues. AstraZeneca is eliminating up to 625 jobs from its operations in Germany in response to difficulties replenishing its product pipeline and pricing cuts imposed by the government, according to a statement on its web site. The cuts are being made due to “delays in the research and development of new drugs as well as to massive state intervention in the pricing of innovative medicines,” the drug maker says. In the scheme of things, 625 positions is not a huge number of job cuts, given the thousands that have been shed by the pharmaceutical industry, including AstraZeneca. Earlier this year, for instance, the drugmaker announced plans to slash 7,300 jobs. It is not clear if the job cuts in Germany are part of this previously announced plan. We asked a spokeperson for comment and will update you accordingly. As we wrote previously, those cuts are designed to save $1.6 billion annually by the end of 2014 and underscore the fallout expected from patent expirations on some of its biggest sellers, notably the Crestor cholesterol pill, the Nexium acid reflux med and the Seroquel antipsychotic.

Read at Pharmalot

Pharmalot
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES